243 related articles for article (PubMed ID: 33428597)
1. Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database.
Gao C; Zhuang J; Li H; Liu C; Zhou C; Liu L; Feng F; Sun C
Aging (Albany NY); 2021 Jan; 13(3):3957-3968. PubMed ID: 33428597
[TBL] [Abstract][Full Text] [Related]
2. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
3. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
[TBL] [Abstract][Full Text] [Related]
4. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
5. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
6. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
7. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
[TBL] [Abstract][Full Text] [Related]
9. Deciphering N
Zhu J; Wang M; Hu D
Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
[TBL] [Abstract][Full Text] [Related]
10. Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y; Fan Q; Guo Y; Zhu K
Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
[No Abstract] [Full Text] [Related]
12. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
15. Prognostic Impact of
Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
[TBL] [Abstract][Full Text] [Related]
17. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.
Li B; Huang Z; Yu W; Liu S; Zhang J; Wang Q; Wu L; Kou F; Yang L
Neoplasia; 2021 Jul; 23(7):704-717. PubMed ID: 34139453
[TBL] [Abstract][Full Text] [Related]
20. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]